Needham & Company LLC Reaffirms Hold Rating for Masimo (NASDAQ:MASI)

Masimo (NASDAQ:MASI)‘s stock had its “hold” rating reissued by equities research analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.

Other equities research analysts also recently issued research reports about the company. Piper Sandler upped their target price on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Wells Fargo & Company lifted their price objective on Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Raymond James increased their target price on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 price target (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, BTIG Research raised their price objective on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Masimo presently has a consensus rating of “Moderate Buy” and a consensus target price of $179.67.

Masimo Price Performance

Masimo stock opened at $176.07 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The company has a market cap of $9.43 billion, a price-to-earnings ratio of 121.43 and a beta of 1.01. The firm has a 50 day moving average price of $169.44 and a 200 day moving average price of $140.91. Masimo has a 1 year low of $101.61 and a 1 year high of $180.97.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. The business had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.63 EPS. Sell-side analysts predict that Masimo will post 4.1 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. B.O.S.S. Retirement Advisors LLC acquired a new position in Masimo in the fourth quarter valued at approximately $881,000. apricus wealth LLC bought a new stake in shares of Masimo in the 4th quarter worth approximately $215,000. RFG Advisory LLC bought a new position in Masimo during the 4th quarter worth $645,000. Nisa Investment Advisors LLC grew its stake in Masimo by 16,740.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,052 shares of the medical equipment provider’s stock worth $835,000 after buying an additional 5,022 shares during the last quarter. Finally, UMB Bank n.a. increased its position in Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 123 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.